Australia risks losing more than jobs in its biopharmaceutical sector — it risks losing strategic capability

Recent waves of job losses across the local biopharmaceutical industry probably mask a deeper, systemic decline in Australia’s capacity to participate in the global life‑sciences ecosystem, with worrying implications for national resilience, patient access to innovation, and the country’s attractiveness as an investment destination. Are we at risk of following New Zealand in losing a strategic national capability? …